Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New standard treatment versus traditional combined androgen blockade in high-risk metastatic castration-sensitive prostate cancer
ChiCTR1900028466Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of docetaxel, abiraterone, prednisone and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Radiographic progression-free survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
docetaxelabirateroneprednisonebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR1900028466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028466.